[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623037":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":70,"collaborators":36,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":36,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":36,"enrollmentInfo":81,"targetDuration":36,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":93,"whyStopped":36,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"AI intervention group","EXPERIMENTAL","Subject will receive with topical betamethasone dipropionate cream (BD) and have a weekly virtual visit with an AI-generated automated physician provider (AIGPP).",[13],"Behavioral: Artificial intelligence",{"label":15,"type":10,"description":16,"interventionNames":17},"Human intervention group","Subjects will receive BD and receive weekly video calls from study staff",[18],"Behavioral: Human",{"label":20,"type":6,"description":21,"interventionNames":22},"Standard of Care Group","Subjects will receive BD and scheduled for a single follow up visit in 4 weeks",[23],"Other: Standard of Care",[25,32,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"BEHAVIORAL","Artificial intelligence","patients will receive BD and have a weekly virtual visit with an AIGPP",[9],[31],"Artificial intelligence (AI)",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Human","patients will receive BD and receive weekly video calls from study staff",[15],null,{"type":6,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"Standard of Care","patients will receive BD and scheduled for a single follow up visit in 4 weeks",[20],[42],{"name":43,"affiliation":5,"role":44},"Steven R Feldman, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":36,"email":50},"Irma M Richardson, MHA","CONTACT","336-716-2903","irma.richardson@advocatehealth.org",[52],{"facility":53,"status":36,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Wake Forest University Health Sciences Department of Dermatology","Winston-Salem","North Carolina","27157","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-80.24422,36.09986,{"lat":63,"lon":62},[66,67,69],{"name":47,"role":48,"phone":49,"phoneExt":36,"email":50},{"name":36,"role":48,"phone":68,"phoneExt":36,"email":36},"336-716-7465",{"name":43,"role":44,"phone":36,"phoneExt":36,"email":36},{"type":71,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100623037","assessing-psoriasis-treatment-outcomes-100623037",false,"NCT07391423","Assessing Psoriasis Treatment Outcomes","Assessing Psoriasis Treatment Outcomes: a Single-center, Prospective Study Evaluating Patient Outcomes in Psoriasis","Inclusion Criteria:\n\n* Patients ≥18 years of age\n* Patients with a current diagnosis of psoriasis suitable for treatment with topical Betamethasone (BD)\n* Patients who live in the United States\n* Patients with a sufficient command of the English language\n* Patients with a mobile device able to at least operate at 25 frames per second (FPS).\n\nExclusion Criteria:\n\n* Patients less than the age of 18\n* Patients with severe or unstable comorbid conditions\n* Patient who are pregnant or breastfeeding\n* Patients with any other skin conditions that prohibit or confound the ability of the investigator to interpret skin findings\n* Patients that are taking concomitant topical or systemic therapy for the treatment of psoriasis and\u002For phototherapy\n* Patients without mobile devices able to at least operate at 25 frames per second (FPS).\n* Patients without a current diagnosis of psoriasis suitable for treatment with topical BD","ALL","18 Years",{"count":82,"type":83},15,"ESTIMATED","INTERVENTIONAL",[86],"NA","To assess the feasibility of AIGPP video interactions with psoriasis patients. To explore patient attitudes, trust, and comfort levels concerning AIGPP interactions in a healthcare setting, and to understand their influence on the patient-physician dynamic. To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video interactions, weekly human video calls, or standard care (single follow up visit after 4 weeks). Adherence rates will be evaluated via a cap designed to record adherence attached to the study medication container.",[89],"Psoriasis",[91,92,27],"Psoriasis Treatment Outcomes","medication adherence","NOT_YET_RECRUITING","2026-08-03",{"date":96,"type":97},"2026-08-04","ACTUAL",{"date":99,"type":83},"2026-10",{"date":101,"type":83},"2029-03",{"name":5,"class":6},1]